Biovail Settles With SEC For $10M
Biovail Corp. will pay $10 million to settle a U.S. Securities and Exchange Commission enforcement action alleging "chronic fraudulent conduct" by the pharmaceutical company, though fraud charges against the company's former...To view the full article, register now.
Already a subscriber? Click here to view full article